First IPO Day in Lausanne on the horizon

IPOs of Swiss tech companies from the life sciences as well as from ICT have become routine in the last months. And more and more start-ups do not longer rule out an IPO as an exit option.

At the IPO Days of Startup Invest companies on the way to an IPO can pitch to an audience and get feedback from investment bankers and IPO advisors in one to one sessions. In addition, start-ups can gain important insights in an IPO workshop. The IPO Day Lausanne will start with Jacques Essinger, representative of Symetis. Symetis prepared for an IPO in 2017 but was acquired by Boston Scientic for more than $400 million shortly before the planned IPO date. After the keynote, investment bankers and advisors will pitch before the selected companies will take the stage.

The selected companies are:

Abionic has developed and commercialized the abioSCOPE, a rapid diagnostic platform used in clinical laboratories and at the point-of-care to improve medical diagnosis. The company raises CHF20 Million in Series C Financing in 2018.

AMAL Therapeutics, the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, announced last year that it has completed a financing round, raising of Euros 8 million.

AMYRA is developing therapeutic product applications for the treatment of celiac disease and gluten sensitivity, which represent major public health issues. AMYRA‘s two lead product candidates are AMY01 for the treatment of celiac disease and AMY02 for the treatment of gluten sensitivity.  AMY01 is in the pre-clinical stage; AMY02 in the lead optimization phase.

CAScination’s advanced stereotactic planning and navigation technology provides healthcare professionals with the tools needed to ensure precise, reproducible and efficient therapy. CAS-One IR has proven to be highly efficient in the treatment of soft tissue liver tumors. To this date more than 1.500 interventions worldwide have been performed successfully. 

Distalmotion aims to make surgical robots simple and affordable. The system of the medtech company is currently being tested in clinical trials.

On the crowdlending platform Lend borrowers and investors are directly connected. This leads to lower interest rates for borrowers and higher returns for investors.

Nanolive has developed microscopes that can be used by scientists to observe living cells in 3D and study the effects of drugs at the cellular level without damage to the cells. Recently the company entered into the data business.

Neeo, a Solothurn based startup with offices in the United States, developed an intelligent home automation system that allows users to switch all electronic devices with only one remote control. The remote control was launched last year after a very successful crowdfunding campaign.

Nexthink developed a new technology that provides IT departments of client companies with real-time visibility of user stations. For 2017 Nexthink reported an increased global customer base including over 200 large enterprises, more partners and staff.

NetGuardians uses advanced analytics, dynamic profiling and machine learning to catch fraudsters before they strike. The company is successful globally and closed a CHF 8.5 million Series C funding a year ago. 

SWISSto12 pioneers the development and industrial supply of Radio-Frequency (RF) antenna, waveguide and filter products based on additive manufacturing (also known as 3D printing). The company obtained the Scale-up Vaud Label last year.

The IPO Day will be held on 13 June at Gotham. More information and registration on the website of the event. Partners of the Event include Euronext and Innovaud.

(SK)